146 related articles for article (PubMed ID: 11206463)
1. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
Mak CC; Le VD; Lin YC; Elder JH; Wong CH
Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases.
Mak CC; Brik A; Lerner DL; Elder JH; Morris GM; Olson AJ; Wong CH
Bioorg Med Chem; 2003 May; 11(9):2025-40. PubMed ID: 12670654
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
Le VD; Mak CC; Lin YC; Elder JH; Wong CH
Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Dunn BM; Pennington MW; Frase DC; Nash K
Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
[TBL] [Abstract][Full Text] [Related]
6. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
8. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.
Kervinen J; Lubkowski J; Zdanov A; Bhatt D; Dunn BM; Hui KY; Powell DJ; Kay J; Wlodawer A; Gustchina A
Protein Sci; 1998 Nov; 7(11):2314-23. PubMed ID: 9827997
[TBL] [Abstract][Full Text] [Related]
9. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
[TBL] [Abstract][Full Text] [Related]
10. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
11. Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
Glenn MP; Pattenden LK; Reid RC; Tyssen DP; Tyndall JD; Birch CJ; Fairlie DP
J Med Chem; 2002 Jan; 45(2):371-81. PubMed ID: 11784141
[TBL] [Abstract][Full Text] [Related]
12. Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Ghosh AK
J Med Chem; 2009 Apr; 52(8):2163-76. PubMed ID: 19323561
[No Abstract] [Full Text] [Related]
13. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
Kiso Y
Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.
Murphy PV; O'Brien JL; Gorey-Feret LJ; Smith AB
Bioorg Med Chem Lett; 2002 Jul; 12(13):1763-6. PubMed ID: 12067556
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
18. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
